Doxorubicin in treatment of malignant solid tumors in children.
D000293:Adolescent; D000328:Adult; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy; D002648:Child; D002675:Child, Preschool; D003110:Colonic Neoplasms / Q000188:drug therapy; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007223:Infant; D008080:Liposarcoma / Q000188:drug therapy; D008113:Liver Neoplasms; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D008297:Male; D008479:Mediastinal Neoplasms / Q000188:drug therapy; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000188:drug therapy*; D009447:Neuroblastoma / Q000188:drug therapy; D009455:Neurofibroma / Q000188:drug therapy; D012516:Osteosarcoma / Q000188:drug therapy; D010997:Pleural Neoplasms / Q000188:drug therapy; D012208:Rhabdomyosarcoma / Q000188:drug therapy; D012512:Sarcoma, Ewing / Q000188:drug therapy; D013724:Teratoma / Q000188:drug therapy; D013997:Time Factors
D004317:Doxorubicin